University of Sheffield, Sheffield, UK.
J Clin Densitom. 2011 Jul-Sep;14(3):181-3. doi: 10.1016/j.jocd.2011.05.013.
The World Health Organization fracture risk assessment tool, FRAX(®), is an advance in clinical care that can assist in clinical decision-making. However, with increasing clinical utilization, numerous questions have arisen regarding how to best estimate fracture risk in an individual patient. Recognizing the need to assist clinicians in optimal use of FRAX(®), the International Osteoporosis Foundation (IOF) in conjunction with the International Society for Clinical Densitometry (ISCD) assembled an international panel of experts that ultimately developed joint Official Positions of the ISCD and IOF advising clinicians regarding FRAX(®) usage. As part of the process, the charge of the FRAX(®) Clinical Task Force was to review and synthesize data surrounding a number of recognized clinical risk factors including rheumatoid arthritis, smoking, alcohol, prior fracture, falls, bone turnover markers and glucocorticoid use. This synthesis was presented to the expert panel and constitutes the data on which the subsequent Official Positions are predicated. A summary of the Clinical Task Force composition and charge is presented here.
世界卫生组织骨折风险评估工具（FRAX(®)）是临床护理的一项进步，可以辅助临床决策。然而，随着临床应用的增加，人们对如何在个体患者中最佳估计骨折风险提出了众多问题。为了帮助临床医生更好地使用 FRAX(®)，国际骨质疏松基金会（IOF）与国际临床密度测定学会（ISCD）联合组建了一个国际专家小组，最终制定了 ISCD 和 IOF 的联合官方立场，就 FRAX(®)的使用为临床医生提供建议。作为该过程的一部分，FRAX(®)临床工作组的任务是审查和综合与一些公认的临床危险因素相关的数据，包括类风湿性关节炎、吸烟、饮酒、既往骨折、跌倒、骨转换标志物和糖皮质激素的使用。该综合报告提交给了专家小组，构成了后续官方立场的依据。这里介绍了临床工作组的组成和任务。
